Published in Blood Weekly, April 18th, 2002
Bayer, Germany's biggest drug maker, said it had signed a letter of intent to take a "substantial majority interest" and management control of the venture, which will have annual sales of more than $2 billion. Bayer also would have an option to buy the stake held by Aventis at a later date.
Bayer is in the midst of an overhaul launched last year to shore up earnings after patient deaths forced it to withdraw the lucrative anti-cholesterol treatment Lipobay,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.